These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 33452850)

  • 21. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial.
    Grainger JD; Locatelli F; Chotsampancharoen T; Donyush E; Pongtanakul B; Komvilaisak P; Sosothikul D; Drelichman G; Sirachainan N; Holzhauer S; Lebedev V; Lemons R; Pospisilova D; Ramenghi U; Bussel JB; Bakshi KK; Iyengar M; Chan GW; Chagin KD; Theodore D; Marcello LM; Bailey CK
    Lancet; 2015 Oct; 386(10004):1649-58. PubMed ID: 26231455
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia.
    Afdhal NH; Giannini EG; Tayyab G; Mohsin A; Lee JW; Andriulli A; Jeffers L; McHutchison J; Chen PJ; Han KH; Campbell F; Hyde D; Brainsky A; Theodore D;
    N Engl J Med; 2012 Aug; 367(8):716-24. PubMed ID: 22913681
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Eltrombopag for Delayed Platelet Recovery and Secondary Thrombocytopenia Following Allogeneic Stem Cell Transplantation in Children.
    Li S; Wu R; Wang B; Fu L; Zhu G; Zhou X; Ma J; Zhang L; Qin M
    J Pediatr Hematol Oncol; 2019 Jan; 41(1):38-41. PubMed ID: 30080752
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Secondary failure of platelet recovery after hematopoietic stem cell transplantation.
    Bruno B; Gooley T; Sullivan KM; Davis C; Bensinger WI; Storb R; Nash RA
    Biol Blood Marrow Transplant; 2001; 7(3):154-62. PubMed ID: 11302549
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Eltrombopag treatment promotes platelet recovery and reduces platelet transfusion for patients with post-transplantation thrombocytopenia.
    Gao F; Zhou X; Shi J; Luo Y; Tan Y; Fu H; Lai X; Yu J; Huang H; Zhao Y
    Ann Hematol; 2020 Nov; 99(11):2679-2687. PubMed ID: 32519094
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of eltrombopag, a thrombopoietin receptor agonist, in post-transplantation thrombocytopenia.
    Reid R; Bennett JM; Becker M; Chen Y; Milner L; Phillips GL; Liesveld J
    Am J Hematol; 2012 Jul; 87(7):743-5. PubMed ID: 22573520
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Eltrombopag can promote platelet implantation after allogeneic hematopoietic stem cell transplantation as safely and similarly to thrombopoietin.
    Li Y; Kong F; Bai G; Jiang Y; Zhang W; Sun X; Sui X; Li Y; Ding M; Yuan D; Wang X; Fang X
    Front Immunol; 2024; 15():1340908. PubMed ID: 38650933
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term eltrombopag in children with chronic immune thrombocytopenia: A single-centre extended real-life observational study in China.
    Wang Z; Wang N; Juntao O; Ma J; Dong S; Meng J; Liu J; Chen Z; Cheng X; Wu R
    Br J Haematol; 2024 Mar; 204(3):1017-1023. PubMed ID: 38087811
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Eltrombopag for Post-Transplantation Thrombocytopenia: Results of Phase II Randomized, Double-Blind, Placebo-Controlled Trial.
    Ahmed S; Bashir Q; Bassett R; Poon MC; Valdez B; Konoplev S; Alousi AM; Andersson BS; Ciurea S; Hosing C; Jones R; Kebriaei P; Khouri I; Kim S; Nieto Y; Olson A; Oran B; Parmar S; Qazilbash MH; Rezvani K; Shah N; Shpall EJ; Champlin R; Popat U
    Transplant Cell Ther; 2021 May; 27(5):430.e1-430.e7. PubMed ID: 33965187
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Eltrombopag for thrombocytopenia in 24 children after hematopoietic stem cell transplantation].
    Liu S; Que LP; Huang K; Fang JP; Wang KM; Zhan LP; Liu DD; Xu HG
    Zhonghua Er Ke Za Zhi; 2021 Apr; 59(4):311-315. PubMed ID: 33775051
    [No Abstract]   [Full Text] [Related]  

  • 31. Eltrombopag reduces bleeding complications and the need of platelet transfusions in cirrhotic thrombocytopenic patients subjected to invasive procedures.
    Castelli R; Gidaro A; Lambertenghi Deliliers G
    Blood Coagul Fibrinolysis; 2021 Mar; 32(2):163-166. PubMed ID: 33555693
    [No Abstract]   [Full Text] [Related]  

  • 32. Efficacy and safety of eltrombopag in Japanese patients with chronic liver disease and thrombocytopenia: a randomized, open-label, phase II study.
    Kawaguchi T; Komori A; Seike M; Fujiyama S; Watanabe H; Tanaka M; Sakisaka S; Nakamuta M; Sasaki Y; Oketani M; Hattori T; Katsura K; Sata M
    J Gastroenterol; 2012 Dec; 47(12):1342-51. PubMed ID: 22674141
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy.
    Afdhal NH; Dusheiko GM; Giannini EG; Chen PJ; Han KH; Mohsin A; Rodriguez-Torres M; Rugina S; Bakulin I; Lawitz E; Shiffman ML; Tayyab GU; Poordad F; Kamel YM; Brainsky A; Geib J; Vasey SY; Patwardhan R; Campbell FM; Theodore D
    Gastroenterology; 2014 Feb; 146(2):442-52.e1. PubMed ID: 24126097
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Eltrombopag for treatment of thrombocytopenia-associated disorders.
    Merli P; Strocchio L; Vinti L; Palumbo G; Locatelli F
    Expert Opin Pharmacother; 2015; 16(14):2243-56. PubMed ID: 26364898
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Eltrombopag for myelodysplastic syndromes or chronic myelomonocytic leukaemia with no excess blasts and thrombocytopenia: a French multicentre retrospective real-life study.
    Comont T; Meunier M; Cherait A; Santana C; Cluzeau T; Slama B; Laribi K; Giraud JT; Dimicoli S; Berceanu A; Le Clech L; Cony-Makhoul P; Gruson B; Torregrosa J; Sanhes L; Jachiet V; Azerad MA; Al Jijakli A; Gyan E; Gaudin C; Broner J; Guerveno C; Guillaume T; Ades PL; Beyne-Rauzy O; Fenaux P;
    Br J Haematol; 2021 Jul; 194(2):336-343. PubMed ID: 34151423
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Eltrombopag as first-line treatment for thrombocytopenia among paediatric patients after allogeneic haematopoietic stem cell transplantation.
    Qiu KY; Liao XY; Huang K; Wu RH; Xu HG; Xu LH; Li Y; Weng WJ; Zhou DH; Fang JP
    Br J Clin Pharmacol; 2021 Apr; 87(4):2023-2031. PubMed ID: 33080064
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial.
    Mittelman M; Platzbecker U; Afanasyev B; Grosicki S; Wong RSM; Anagnostopoulos A; Brenner B; Denzlinger C; Rossi G; Nagler A; Garcia-Delgado R; Portella MSO; Zhu Z; Selleslag D
    Lancet Haematol; 2018 Jan; 5(1):e34-e43. PubMed ID: 29241762
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hemostatic challenges in patients with chronic immune thrombocytopenia treated with eltrombopag.
    Tarantino MD; Bakshi KK; Brainsky A
    Platelets; 2014; 25(1):55-61. PubMed ID: 23402314
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of eltrombopag on platelet count and platelet activation in Wiskott-Aldrich syndrome/X-linked thrombocytopenia.
    Gerrits AJ; Leven EA; Frelinger AL; Brigstocke SL; Berny-Lang MA; Mitchell WB; Revel-Vilk S; Tamary H; Carmichael SL; Barnard MR; Michelson AD; Bussel JB
    Blood; 2015 Sep; 126(11):1367-78. PubMed ID: 26224646
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Eltrombopag use in a patient with Wiskott-Aldrich syndrome.
    Gabelli M; Marzollo A; Notarangelo LD; Basso G; Putti MC
    Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28643468
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.